About 1 in 7 US adults starting semaglutide were given an off-label high first dose, and those patients had a 25% higher rate of stopping the drug early and were less likely to still be on it a year later

A peer-reviewed real-world retrospective cohort by Belalcazar et al. showed that among 48,658 US adults initiating injectable semaglutide, 14.5% started at an off-label high dose (>=1 mg/week), and that group had a higher risk of discontinuing the drug early.